ITM-Radiopharma
ITM Isotope Technologies Munich SE is a privately held radiopharmaceutical biotech company that develops and supplies targeted radiopharmaceutical therapeutics and diagnostics, combining proprietary Lutetium-177 and Actinium-225 radioisotopes with targeting molecules for hard-to-treat tumors in oncology and nuclear medicine.
- Company typePrivate
- Founded2004
- HeadquartersGarching Bei München, Germany
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What ITM-Radiopharma does
ITM Isotope Technologies Munich SE (ITM Radiopharma) is a privately held radiopharmaceutical biotech company founded in 2004 as a spin-off from the Technical University of Munich, headquartered in Garching near Munich, Germany, with a U.S. regional headquarters in Princeton, New Jersey. The company develops and supplies targeted radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors, combining proprietary medical radioisotopes—notably non-carrier-added (n.c.a.) Lutetium-177 and Actinium-225—with targeting molecules such as edotreotide, PSMA ligands, and somatostatin receptor antagonists to deliver precision radiation to cancer cells. Its clinical pipeline spans ITM-11 (n.c.a. 177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors, which met its Phase 3 COMPETE primary endpoint with a statistically significant improvement in progression-free survival (23.9 vs 14.1 months vs everolimus, p=0.022), ITM-31 for glioblastoma, ITM-22 for prostate cancer, and an emerging Terbium-161 program (ITM-63, ITM-23). Manufacturing is anchored by the IAZ Production Facility co-located with the FRM II research reactor in Garching and the NOVA Production Facility in Neufahrn, with a global supply network reinforced by a long-standing technology transfer agreement with NTP Radioisotopes in South Africa.
The company operates a B2B enterprise sales motion with three revenue streams: radioisotope supply (Lutetium-177 n.c.a. and Actinium-225) sold to hospitals, pharmaceutical companies, and radiopharmacies; investigational radiopharmaceutical supply through clinical trials and expanded access programs targeting oncology centers and nuclear medicine departments; and radiolabeling technical services and equipment provision. Specialized sales channels—RadioisotopeOperations, RadiopharmaOperations, and TechnicalServices—route customer inquiries to the appropriate operational team. Marketing is driven by scientific engagement through major oncology and nuclear medicine conferences (ASCO, SNMMI, EANM, ENETS, ESMO, NANETS), peer-reviewed publications, and a registered healthcare-professional portal, with corporate communications amplified via LinkedIn and YouTube. Capital structure is anchored by a USD 262.5 million non-dilutive debt facility transferred from Blue Owl Managed Funds to Perceptive Advisors in June 2026, supporting pipeline advancement and commercial-scale manufacturing build-out ahead of ITM-11's anticipated regulatory and commercial milestones.
ITM-Radiopharma firmographics
Firmographics- Name
- ITM-Radiopharma
- Legal name
- ITM Isotope Technologies Munich SE
- Website
- https://itm-radiopharma.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- ITM Isotope Technologies Munich SE is a privately held radiopharmaceutical biotech company that develops and supplies targeted radiopharmaceutical therapeutics and diagnostics, combining proprietary Lutetium-177 and Actinium-225 radioisotopes with targeting molecules for hard-to-treat tumors in oncology and nuclear medicine.
- Ownership category
- akta.pro rank
ITM-Radiopharma industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH), Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
Keywords
Where ITM-Radiopharma is headquartered
LocationHeadquarters
- HQ city
- Garching Bei München
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
ITM-Radiopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Infrastructure, Personnel, Marketing or Sales, Operations
Revenue model
- Radioisotope Supply: ITM supplies medical radioisotopes (Lutetium-177 n.c.a., Actinium-225) to hospitals, pharmaceutical companies, and radiopharmacies globally. This includes both research-grade and GMP-quality isotopes for diagnostic and therapeutic applications.
- Radiopharmaceutical Products: Proprietary radiopharmaceutical therapeutics and diagnostics in clinical development, targeting neuroendocrine tumors, prostate cancer, and glioblastoma. The company operates clinical trial programs and expanded access programs for investigational products.
- Technical Services and Equipment: Radiolabeling services and equipment provision for hospitals and radiopharmacies preparing radiopharmaceuticals for clinical use.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
ITM-Radiopharma product offering
Product offeringCore offering
ITM-Radiopharma develops and manufactures targeted radiopharmaceutical therapeutics and diagnostics for precision oncology, combining proprietary radioisotopes (non-carrier-added Lutetium-177 and Actinium-225) with targeting molecules to treat hard-to-treat tumors such as neuroendocrine tumors, prostate cancer, and glioblastoma. The company operates a vertically integrated model spanning radioisotope production at the FRM II research reactor, GMP-certified radiopharmaceutical manufacturing, and global clinical development, supplying both investigational drug products and medical radioisotopes to hospitals, nuclear medicine departments, and clinical trial sites.
Product overview
ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company that develops a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. The company's offering comprises a broad precision oncology pipeline combining high-quality radioisotopes (Lutetium-177, Actinium-225) with targeting molecules. Key therapeutic candidates include ITM-11 (¹⁷⁷Lu-edotreotide) for neuroendocrine tumors which completed Phase 3 COMPETE trial, ITM-31 for glioblastoma, and ITM-22 for prostate cancer. ITM operates from manufacturing facilities in Germany (Garching, Neufahrn) with a U.S. headquarters in Princeton, NJ, leveraging two decades of radiopharma expertise and established global supply networks.
Differentiator
Problem solved
Functional benefit
Products and services
- ITM-11 (n.c.a. 177Lu-edotreotide) Proprietary targeted radiotherapeutic investigational agent combining non-carrier-added Lutetium-177 with edotreotide for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs); supplied to clinical trial sites and Expanded Access Programs through Medical Affairs.
- ITM-31 Investigational targeted radiotherapeutic candidate for glioblastoma developed as part of ITM's precision oncology pipeline.
- ITM-22 (ITM-24d) Investigational targeted radiotherapeutic candidate for prostate cancer, part of ITM's precision oncology pipeline.
- ITM-63 (Terbium-161 DOTA-LM3) Investigational somatostatin receptor antagonist radiolabeled with Terbium-161 for treatment of gastroenteropancreatic neuroendocrine tumors; Phase 0 study ongoing.
- ITM-23 (161Tb-SibuDAB) Investigational PSMA ligand radiolabeled with Terbium-161 for targeted radionuclide therapy in metastatic prostate cancer; Phase Ia/b study ongoing.
- Lutetium-177 (n.c.a.) Non-carrier-added Lutetium-177 medical radioisotope supplied globally by ITM for use as a key component in radiopharmaceutical therapeutics and diagnostics for precision oncology applications, sold to hospitals, radiopharmacies, and pharmaceutical companies.
- Actinium-225 Alpha-emitting medical radioisotope supplied by ITM for targeted radionuclide therapy applications; ITM is developing production capabilities for global supply.
- COMPETE Phase 3 Trial Phase 3 randomized controlled clinical trial (NCT03049189) evaluating 177Lu-edotreotide vs everolimus in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors, which met its primary PFS endpoint.
- COMPOSE Phase 3 Trial Phase 3 clinical study evaluating 177Lu-edotreotide in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
- Radiolabeling Services and Equipment Radiolabeling services and equipment provision for hospitals and radiopharmacies preparing radiopharmaceuticals for clinical use, delivered through ITM's Technical Services team.
Quantifiable outcome
- ITM-11 demonstrated clinically and statistically significant improvement in progression-free survival (23.9 vs 14.1 months) compared to everolimus in GEP-NET patients (p=0.022)
- +3 more outcomes
Companies that use ITM-Radiopharma
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles3 records
ITM-Radiopharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ITM-Radiopharma partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Technical University of Munich (TUM)coreLong-standing collaboration with Technical University of Munich's FRM II research reactor and Klinikum rechts der Isar for radioisotope production and clinical research. Prof. Wolfgang Weber, Director of Nuclear Medicine at TUM, serves as a key opinion leader and collaborator.
- NTP Radioisotopes (South Africa)coreTechnology transfer agreement concluded in 2012 with NTP Radioisotopes for reliable and sustainable supply of n.c.a. 177Lu from NTP's GMP-certified facility in Pretoria, South Africa. Supports global supply chain reliability.
- ETH Zurich - PSI (Switzerland)coreCollaboration with Center for Radiopharmaceutical Sciences ETHZ-PSI for development of novel radiopharmaceuticals including PSMA radioligands and terbium-based therapies. Prof. Roger Schibli and Prof. Cristina Müller serve as key research collaborators.
- University Hospital BaselcoreClinical research collaboration with Dr. Julia Fricke and Prof. Damian Wild for GEP-NET studies including ITM-63 (DOTA-LM3 terbium-161) and other SSTR-targeting programs. Award-winning research partnership recognized with EANT Marie Curie Award 2024.
- International Centers for Precision Oncology (ICPO) FoundationcoreITM supported the ICPO Forum for Theranostics in Precision Oncology, hosted at ITM's headquarters campus in Garching/Munich. Collaborative event bringing together key opinion leaders in precision oncology and theranostics.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
ITM-Radiopharma competitors and assessment
Company assessmentDirect peers
- Lantheus Holdings: U.S. radiopharmaceutical-focused company with a portfolio spanning diagnostic imaging agents (e.g., Pylarify PSMA PET) and an emerging radiotherapeutic pipeline (including 177Lu-PSMA assets). Highly comparable in business model as a vertically integrated diagnostic + therapeutic radiopharma specialist.
- Orano Med: Subsidiary of Orano developing lead-212-based alpha-emitter targeted radiotherapies for oncology. Comparable as a next-generation radionuclide therapy developer pursuing a parallel non-Lu-177 platform — directly relevant to ITM's Tb-161/Ac-225 strategy.
- Telix Pharmaceuticals: Commercial-stage radiopharma company developing and commercializing diagnostic and therapeutic radiopharmaceuticals (Illuccix for PSMA imaging, TLX591 177Lu-rosopatamab for prostate cancer). Closely comparable precision-oncology radiopharma peer with overlapping Lu-177 PSMA and imaging agents.
- Bracco Imaging: Privately held diagnostic imaging company with a growing radiopharmaceutical franchise (Blue Earth Diagnostics — Axumin, Posluma). Comparable as a global diagnostic radiopharma manufacturer and commercializer, with ambitions extending into therapeutics.
- PharmaLogic: U.S.-based contract manufacturer and radiopharmacy network producing and distributing PET and SPECT agents, including emerging Lu-177 therapeutic capabilities. Comparable vertically integrated radiopharmacy/CDMO model serving overlapping hospital customers.
- Curium Pharma: One of the world's largest radiopharmaceutical manufacturers, supplying diagnostic and therapeutic nuclear medicine products to hospitals globally. Directly comparable as a vertically integrated radiopharma manufacturer with overlapping isotope and finished-dose capabilities.
Broad incumbents
- Novartis: Global pharma major with approved radioligand therapies Lutathera (177Lu-DOTATATE for GEP-NETs) and Pluvicto (177Lu-PSMA-617 for mCRPC), the dominant incumbents in the exact indications ITM-11 is targeting. Most relevant competitive benchmark for commercial trajectory and pricing dynamics.
- Bayer: Major pharma with Xofigo (radium-223) in the radiopharmaceutical space and a growing pipeline of targeted radionuclide therapies (e.g., Nubeqa-AlphaMedix combinations). Broad incumbent in oncology with overlapping radioligand interests.
Others
- GE HealthCare: Global medical imaging and life sciences company with a sizable radiopharma manufacturing and distribution business (including 68Ga, 177Lu and theranostic offerings post-MPH acquisition). Broad incumbent with comparable manufacturing footprint and customer base.
Emerging players
- PanTera: Belgian startup spun out of SCK CEN focused on large-scale Actinium-225 production for alpha-emitting radiopharmaceuticals. Comparable emerging supplier addressing the same next-generation radionuclide bottleneck ITM is targeting with its Ac-225 program.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
ITM-Radiopharma social profiles
Digital presenceITM-Radiopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
ITM-Radiopharma leadership team
Management profileNumber of profiles
Profiles7 records
ITM-Radiopharma subsidiaries and ownership
Company hierarchySubsidiaries6 records
ITM-Radiopharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ITM-Radiopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ITM-Radiopharma
What does ITM-Radiopharma do?
ITM-Radiopharma develops and manufactures targeted radiopharmaceutical therapeutics and diagnostics for precision oncology, combining proprietary radioisotopes (non-carrier-added Lutetium-177 and Actinium-225) with targeting molecules to treat hard-to-treat tumors such as neuroendocrine tumors, prostate cancer, and glioblastoma. The company operates a vertically integrated model spanning radioisotope production at the FRM II research reactor, GMP-certified radiopharmaceutical manufacturing, and global clinical development, supplying both investigational drug products and medical radioisotopes to hospitals, nuclear medicine departments, and clinical trial sites.
Is ITM-Radiopharma a public or private company?
ITM-Radiopharma is a private company. It is classified as unknown and is currently operating.
When was ITM-Radiopharma founded?
ITM-Radiopharma was founded in 2004. It employs 501 to 1,000 people.
Where is ITM-Radiopharma based?
ITM-Radiopharma is headquartered in Garching Bei München, Germany, in the Europe region.
How does ITM-Radiopharma make money?
Three revenue lines are on record. Radioisotope Supply is the primary driver. The others are radiopharmaceutical Products and technical Services and Equipment.
Who are ITM-Radiopharma's main competitors?
Direct peers on record are Lantheus Holdings, Orano Med, Telix Pharmaceuticals, Bracco Imaging, PharmaLogic and Curium Pharma. Broad incumbents are Novartis and Bayer. GE HealthCare is listed as an others. PanTera is listed as an emerging player.
Does ITM-Radiopharma have an API?
No public API is recorded for ITM-Radiopharma.
What industry is ITM-Radiopharma in?
ITM-Radiopharma's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma). Its NAICS code is 3254 and its SIC code is 2834.